Home / Stocks / REGN

Regeneron Pharmaceuticals (REGN, Biotechnology) Stock Valuation & Fair Value Fairly valued

Regeneron Pharmaceuticals (REGN, Biotechnology) trades at a blended P/E of 16.2, about 28% below its historical normal valuation, with a forward growth estimate of 13.2% and a PEG of 1.23. Analysts' one-year estimates have been hit 55% of the time.

DATA AS OF 2026-08-21
Blended P/E
16.2
Normal P/E
22.6
PEG
1.23
Fwd growth
13.2%
Div yield
0.5%
RSI (14)
79.0
Overbought

The Street vs SeerForecast

Wall Street's mean price target for REGN is $833.65 across 27 analysts, 0.0% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-03) to fairly valued (2026-08-21).

Price and rating by weekClose moved +29.8 percent from 2026-06-03 to 2026-08-17, with 1 rating change over 20 recorded weeks.2026-06-03: Quality business with a solid forward outlook, close 618.95 (recalculated)2026-06-10: Quality business with a solid forward outlook, close 601.65 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 612.14 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 614.73 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 609.94 (recalculated)2026-07-02: Quality business with a solid forward outlook, close 654.27 (recalculated)2026-07-06: Quality business with a solid forward outlook, close 649.81 (recalculated)2026-07-09: Quality business with a solid forward outlook, close 667.95 (recalculated)2026-07-12: Quality business with a solid forward outlook, close 664.52 (recalculated)2026-07-13: Quality business with a solid forward outlook, close 663.09 (recalculated)2026-07-14: Quality business with a solid forward outlook, close 656.12 (recalculated)2026-07-20: Quality business with a solid forward outlook, close 672.15 (recalculated)2026-07-22: Quality business with a solid forward outlook, close 651.18 (recalculated)2026-07-25: Fairly valued, close 656.01 (recalculated)2026-07-27: Fairly valued, close 667.17 (recalculated)2026-07-31: Fairly valued, close 762.63 (recalculated)2026-08-03: Fairly valued, close 762.632026-08-07: Fairly valued, close 784.36 (recalculated)2026-08-10: Fairly valued, close 784.362026-08-17: Fairly valued, close 803.486198032026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 13.6-40%Quality business with a solid forward outlook
2026-06-10P/E 13.9-38%Quality business with a solid forward outlook
2026-06-14P/E 13.9-38%Quality business with a solid forward outlook
2026-06-16P/E 13.9-38%Quality business with a solid forward outlook
2026-06-21P/E 13.9-38%Quality business with a solid forward outlook
2026-07-02P/E 13.6-40%Quality business with a solid forward outlook
2026-07-06P/E 14.3-37%Quality business with a solid forward outlook
2026-07-09P/E 14.3-37%Quality business with a solid forward outlook
2026-07-12P/E 14.5-36%Quality business with a solid forward outlook
2026-07-13P/E 14.5-36%Quality business with a solid forward outlook
2026-07-14P/E 14.5-36%Quality business with a solid forward outlook
2026-07-20P/E 14.8-34%Quality business with a solid forward outlook
2026-07-22P/E 14.8-34%Quality business with a solid forward outlook
2026-07-25P/E 14.4-36%Fairly valued
2026-07-27P/E 14.4-36%Fairly valued
2026-07-31P/E 14.8-35%Fairly valued
2026-08-03P/E 15.2-33%Fairly valued
2026-08-07P/E 15.3-32%Fairly valued
2026-08-10P/E 15.5-31%Fairly valued
2026-08-17P/E 15.8-30%Fairly valued
2026-08-21P/E 16.2-28%Fairly valued ← now

Frequently asked questions

Is Regeneron Pharmaceuticals stock overvalued?

At a blended P/E of 16.2 versus its historical normal P/E of 22.6, Regeneron Pharmaceuticals trades about 28% below its typical valuation, with a PEG of 1.23 on 13.2% forward growth. tickerseer currently rates it fairly valued.

What is Regeneron Pharmaceuticals's fair value and PEG?

Regeneron Pharmaceuticals trades at a blended P/E of 16.2 against a historical normal P/E of 22.6, a PEG of 1.23, and a forward growth estimate of 13.2%.

Has tickerseer's rating of Regeneron Pharmaceuticals changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-03) to fairly valued (2026-08-21).

What is the analyst price target for Regeneron Pharmaceuticals?

The mean Wall Street price target for Regeneron Pharmaceuticals is $833.65 across 27 analysts, 0.0% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track REGN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.